A clinical pharmacologic study of chemotherapy and x-ray therapy in lung cancer

Thomas C. Hall, Margarida M. Dederick, Thomas C. Chalmers, Melvin J. Krant, Bruce I. Shnider, John J. Lynch, James F. Holland, Charles Ross, C. Ronald Koons, Albert H. Owens, Emil Frei, Clyde Brindley, Sherwood P. Miller, Seymour Brenner, Henry F. Hosley, Kenneth B. Olson

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Actinomycin D and 5-fluorouracil, given with x-ray in a dosage regimen sufficient to produce definite but tolerable gastrointestinal and marrow toxicity, did not increase the percentage of patients with carcinoma of the lung showing shrinkage of lesions in the irradiated field. There was no evidence of a more rapid onset of shrinkage of the tumor or of an additive effect at subtotal doses of x-ray. Patient survival was not affected beneficially by the addition of the chemotherapeutic agents. Toxicity was not correlated with responses induced. Patients classified as responders to therapy lived longer than those classified as nonresponders.

Original languageEnglish
Pages (from-to)186-193
Number of pages8
JournalAmerican Journal of Medicine
Volume43
Issue number2
DOIs
StatePublished - Aug 1967
Externally publishedYes

Fingerprint

Dive into the research topics of 'A clinical pharmacologic study of chemotherapy and x-ray therapy in lung cancer'. Together they form a unique fingerprint.

Cite this